Javier Juega
Overview
Explore the profile of Javier Juega including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clos-Sansalvador M, Taco O, Rodriguez-Martinez P, Garcia S, Font-Moron M, Bover J, et al.
J Transl Med
. 2024 Nov;
22(1):1030.
PMID: 39548536
Background: Interstitial fibrosis and tubular atrophy (IFTA) is a critical factor in the prognosis of kidney health. Currently, IFTA quantitation in kidney biopsy samples is crucial for diagnosis and assessing...
2.
Romero-Gonzalez G, Argaiz E, Koratala A, Gonzalez D, Vives M, Juega J, et al.
Nefrologia (Engl Ed)
. 2024 Mar;
44(1):5-9.
PMID: 38429147
No abstract available.
3.
Lopez V, Mazuecos A, Villanego F, Lopez-Oliva M, Alonso A, Beneyto I, et al.
Nefrologia (Engl Ed)
. 2023 Nov;
43(5):531-545.
PMID: 37957107
SARS-CoV-2 infection (COVID-19) has had a significant impact on transplant activity in our country. Mortality and the risk of complications associated with COVID-19 in kidney transplant recipients (KT) were expected...
4.
Lopez V, Mazuecos A, Villanego F, Lopez-Oliva M, Alonso A, Beneyto I, et al.
Nefrologia
. 2022 Nov;
PMID: 36405492
SARS-CoV-2 infection (COVID-19) has had a significant impact on transplant activity in our country. Mortality and the risk of complications associated with COVID-19 in kidney transplant recipients (KT) were expected...
5.
Cacho J, Burgos E, Molina M, Villegas A, Perez M, Canas L, et al.
Nefrologia (Engl Ed)
. 2022 Oct;
42(3):311-317.
PMID: 36210620
Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in Kidney transplant (KT)...
6.
Bonjoch A, Juega J, Echeverria P, Puig J, Perez-Alvarez N, Bonal J, et al.
HIV Med
. 2022 Apr;
23(10):1078-1084.
PMID: 35470944
Background: Advanced kidney disease is an emerging problem in people living with HIV despite sustained viral suppression. Methods: We performed a prospective cohort study to identify people living with HIV...
7.
Perez-Saez M, Juega J, Zapatero A, Comas J, Tort J, Lauzurica R, et al.
Transpl Int
. 2021 Oct;
34(12):2507-2514.
PMID: 34664327
The number of kidney transplant (KT) procedures with controlled donation after circulatory death (cDCD) donors has exponentially increased in Spain in recent years, with a parallel increase in donor and...
8.
Molina M, Burgos E, Cacho J, Juega J, Canas L, Taco O, et al.
Transplant Proc
. 2021 Sep;
53(8):2476-2480.
PMID: 34481646
Background: The treatment of coronavirus disease 2019 (COVID-19) is based on the patient's clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in kidney transplant (KT)...
9.
Cacho J, Burgos E, Molina M, Villegas A, Perez M, Canas L, et al.
Nefrologia
. 2021 Jul;
42(3):311-317.
PMID: 34305226
Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in kidney transplant (KT)...
10.
Carreras-Planella L, Cucchiari D, Canas L, Juega J, Franquesa M, Bonet J, et al.
J Nephrol
. 2020 Dec;
34(3):861-874.
PMID: 33275196
Background: In kidney transplantation, fibrosis represents the final and irreversible consequence of the pathogenic mechanisms that lead to graft failure, and in the late stages it irremediably precedes the loss...